EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Venetoclax Combined With FLAG ‐ IDA in Refractory or Relapsed Acute Myeloid Leukemia

Kai Wille iD, Marvin Dumke, Nadine Wilsdorf, Parvis Sadjadian, Artur Schneider, Stephanie Jender-Bartling, Vera Kolatzki, Anette Horstmann, Raphael Meixner, Marina Jiménez-Muñoz, Christiane Fuchs, Hans-Joachim Tischler und 1 weitere

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Kai Wille und 12 weiteren Autor:innen. Beteiligte Einrichtung: University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden,…. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The prognosis of patients with refractory or relapsed AML (R/R‐AML) is very limited. To (re)achieve complete remission, there has recently been increasing evidence that the combination of venetoclax (VEN) with chemotherapy is associated with improved outcomes. Patients and Methods Our retrospective, single‐center study of 53 R/R‐AML patients with a median follow‐up time of 11.0 months compared standard salvage chemotherapy (FLAG‐Ida or HAM in n = 35 patients) with a combination of venetoclax (VEN) and FLAG‐Ida (FLAVIDA in n = 18 patients) concerning safety and efficacy.

Results

Regarding the primary endpoints, there was a statistically significant increased event free survival (EFS) in the FLAVIDA group compared to patients with standard chemotherapy based on the univariate log‐rank‐test and in the multivariate Cox regression analysis (HR 0.22 [95% CI 0.05, 0.97]). There were no differences between the two groups in terms of patients developing febrile neutropenia CTCAE III° and IV° or a delay in hematological recovery. In addition, a clear trend towards an improved overall response rate (78% vs. 51%) was demonstrated in the FLAVIDA group.

Conclusions

The FLAVIDA regimen represents a promising treatment alternative for R/R AML patients with a high response rate and significantly improved EFS compared to standard chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bridged Bicyclo Compounds, HeterocyclicSulfonamidesLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsCytarabineHumansMaleFemaleMiddle AgedAgedAdultRetrospective StudiesIdarubicinVidarabineTreatment OutcomeRecurrenceSalvage TherapyDrug Resistance, NeoplasmPrognosisAged, 80 and overGranulocyte Colony-Stimulating Factor

Stichwörter der Autor:innen

FLAVIDAacute myelocytic leukemia (AML) leukemiarefractoryrelapsedvenetoclax

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesCytarabineIdarubicinVidarabineGranulocyte Colony-Stimulating Factor

Autor:innen und Institutionen

  • University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
  • Core Facility Statistical Consulting, Helmholtz Zentrum München, Munich, Germany.
  • Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany.

ORCID-Profile: Kai Wille

Zitieren

APA

Wille, K., Dumke, M., Wilsdorf, N., Sadjadian, P., Schneider, A., Jender-Bartling, S., Kolatzki, V., Horstmann, A., Meixner, R., Jiménez-Muñoz, M., Fuchs, C., Tischler, H. J., & Griesshammer, M. (2025). Venetoclax Combined With FLAG ‐ IDA in Refractory or Relapsed Acute Myeloid Leukemia. European Journal of Haematology. https://doi.org/10.1111/ejh.14302

Vancouver

Wille K, Dumke M, Wilsdorf N, Sadjadian P, Schneider A, Jender-Bartling S, et al. Venetoclax Combined With FLAG ‐ IDA in Refractory or Relapsed Acute Myeloid Leukemia. European Journal of Haematology. 2025. doi:10.1111/ejh.14302

BibTeX
@article{Wille2025,
  author = {Wille, Kai and Dumke, Marvin and Wilsdorf, Nadine and Sadjadian, Parvis and Schneider, Artur and Jender-Bartling, Stephanie and Kolatzki, Vera and Horstmann, Anette and Meixner, Raphael and Jiménez-Muñoz, Marina and Fuchs, Christiane and Tischler, Hans-Joachim and Griesshammer, Martin},
  title = {Venetoclax Combined With FLAG ‐ IDA in Refractory or Relapsed Acute Myeloid Leukemia},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14302}
}
Kostenlos starten →